Rodimedi & Associates, Inc.

Rodimedi & Associates, Inc. specializes in single-use medical devices, including hypodermic needles, insulin syringes (both basic and safety variants), and in-vitro diagnostic (IVD) kits. Their IVD portfolio covers faecal occult blood testing, erythrocyte sedimentation rate (ESR) measurements, and rapid immunochromatographic test (ICT) kits for detecting respiratory syncytial virus (RSV) antigens in clinical settings. These products are designed for direct patient use or diagnostic purposes.

Rodimedi & Associates, Inc. is based in the United States. Since the company operates within the U.S., its devices are subject to FDA regulations, including classification under the agency’s risk-based system. The U.S. regulatory framework ensures that devices comply with safety and performance standards before entering the market, though individual devices—not the company—are authorised for use.

Rodimedi & Associates, Inc.’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. The UDI system provides a standardized identifier for medical devices, improving traceability and regulatory tracking. Listing in this database helps healthcare providers, regulators, and other stakeholders verify the legitimacy and classification of the devices.

Rodimedi & Associates, Inc.’s devices fall under FDA’s Class I and Class II categories. Class I devices generally pose minimal risk and are subject to general controls, while Class II devices require additional performance standards due to moderate risk. The classification depends on factors like the device’s intended use, potential harm, and the body’s interaction with it, ensuring appropriate regulatory oversight tailored to the device’s risk level.